Jill Roberts Center for Inflammatory Bowel Disease

Publications

Found 60 results
Author Title [ Type(Asc)] Year
Filters: First Letter Of Last Name is M  [Clear All Filters]
Journal Article
Marion JF, Waye JD, Present DH, Israel Y, Bodian C, Harpaz N, Chapman M, Itzkowitz S, Steinlauf AF, Abreu MT et al..  2008.  Chromoendoscopy-targeted biopsies are superior to standard colonoscopic surveillance for detecting dysplasia in inflammatory bowel disease patients: a prospective endoscopic trial.. Am J Gastroenterol. 103(9):2342-9.
Huang C, Haritunians T, Okou DT, Cutler DJ, Zwick ME, Taylor KD, Datta LW, Maranville JC, Liu Z, Ellis S et al..  2015.  Characterization of genetic loci that affect susceptibility to inflammatory bowel diseases in African Americans.. Gastroenterology. 149(6):1575-86.
Huang C, Haritunians T, Okou DT, Cutler DJ, Zwick ME, Taylor KD, Datta LW, Maranville JC, Liu Z, Ellis S et al..  2015.  Characterization of genetic loci that affect susceptibility to inflammatory bowel diseases in African Americans.. Gastroenterology. 149(6):1575-86.
Huang C, Haritunians T, Okou DT, Cutler DJ, Zwick ME, Taylor KD, Datta LW, Maranville JC, Liu Z, Ellis S et al..  2015.  Characterization of genetic loci that affect susceptibility to inflammatory bowel diseases in African Americans.. Gastroenterology. 149(6):1575-86.
Huang C, Haritunians T, Okou DT, Cutler DJ, Zwick ME, Taylor KD, Datta LW, Maranville JC, Liu Z, Ellis S et al..  2015.  Characterization of genetic loci that affect susceptibility to inflammatory bowel diseases in African Americans.. Gastroenterology. 149(6):1575-86.
Agrawal M, Arora S, Li J, Rahmani R, Sun L, Steinlauf AF, Mechanick JI, Zaidi M.  2011.  Bone, inflammation, and inflammatory bowel disease.. Curr Osteoporos Rep. 9(4):251-7.
Battat R, Dulai PS, Casteele NVande, Evans E, Hester KD, Webster E, Jain A, Proudfoot JA, Mairalles A, Neill J et al..  2019.  Biomarkers Are Associated With Clinical and Endoscopic Outcomes With Vedolizumab Treatment in Ulcerative Colitis.. Inflamm Bowel Dis. 25(2):410-420.
Battat R, Ma C, Jairath V, Khanna R, Feagan BG.  2019.  Benefit-Risk Assessment of Vedolizumab in the Treatment of Crohn's Disease and Ulcerative Colitis.. Drug Saf. 42(5):617-632.
Battat R, Kopylov U, Bessissow T, Bitton A, Cohen A, Jain A, Martel M, Seidman E, Afif W.  2017.  Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn's Disease.. Clin Gastroenterol Hepatol. 15(9):1427-1434.e2.
Viladomiu M, Metz ML, Lima SF, Jin W-B, Chou L, Guo C-J, Diehl GE, Simpson KW, Scherl EJ, Longman RS.  2021.  Adherent-invasive E. coli metabolism of propanediol in Crohn's disease regulates phagocytes to drive intestinal inflammation.. Cell Host Microbe.